此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer (ALTAK)

2018年1月23日 更新者:Centre Oscar Lambret

Prevalence and Risk Factors for Persistent Tobacco or Alcohol Use Over the First Year of a First Lung or Head and Neck Cancer

This is an multicenter study for preventive and therapeutic strategies for patients with head and neck cancer

研究概览

地位

完全的

条件

详细说明

Continuing the chronic intoxication by either tobacco or alcohol after the initial diagnosis of a first lung or head and neck cancer significantly improves the risk of experiencing a second cancer, and largely affects the long term survival. Addiction intervention programs should be personalized according to the patient's profile, with the aim to develop more sustained intervention and monitoring in patients identified at higher risk of not spontaneously stopping harmful substance use. As of today, the trajectories of smoking and drinking habits and the risk factors for persisting smoking or drinking habits have been insufficiently explored among patients with a first lung or head and neck cancer.

The ALTAK study aims to depict the rate of tobacco smokers 12 months after the initial diagnosis of a first lung or head and neck cancer. The secondary objectives of the study are:

  • to depict the rate of alcohol users 12 months after the initial diagnosis of a H&N cancer
  • to depict the rate of tobacco smokers at cancer diagnosis
  • to depict the rate of alcohol users at cancer diagnosis
  • to determine the social, motivational, psychiatric, tobacco-related, alcohol-related, and cannabis-related features associated with stopping tobacco in the year following the diagnosis of a first TARC.
  • to determine the social, psychiatric, tobacco-related, alcohol-related, and cannabis-related features associated with stopping alcohol drinking in the year following the diagnosis of a first H&N cancer

研究类型

观察性的

注册 (实际的)

385

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Lille、法国、59020
        • Oscar Lambret Center
      • Lille、法国、59 037
        • Centre Hospitalier Régional et Universitaire - Hopital HURIEZ
      • Lille、法国、59 037
        • Centre Hospitalier Régional et Universitaire - Hopital CALMETTE

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

取样方法

非概率样本

研究人群

patient with a first head and neck cancer or first lung cancer

描述

Inclusion Criteria:

  • first head and neck or lung cancer
  • first support
  • age ≥ 18
  • patient covered by health insurance
  • signed informed consent

Exclusion Criteria:

  • prior lung or head and neck cancer
  • History of another cancer <5 years, not evolutive and untreated at baseline (carcinoma of the cervix, or basal cell carcinoma of the skin properly treated are allowed). The presence of a second discovery tumor location at the same time as the lung or head and neck cancer, is not a criteria for non-inclusion
  • mesothelioma and oesophageal cancer
  • unable to undergo trail medical follow up (geographical, social and psychological reasons)
  • pregnant or nursing women
  • patient under guardianship

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
head and neck or lung cancer
patient with a first head and neck cancer or first lung cancer
  • Socio-economic conditions and general features: educational level, professional status...
  • Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...
  • in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...
  • Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...
  • Assessment of current use of cannabis using the Cannabis Abuse Screening Test
  • Psychiatric assessment using the MINI 5.0

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
tobacco consumption
大体时间:at 12 months
reported tobacco smoking
at 12 months

次要结果测量

结果测量
措施说明
大体时间
tobacco smoking
大体时间:at baseline, 3 and 6 months
frequency tobacco consumption
at baseline, 3 and 6 months
alcohol drinking
大体时间:at baseline, 3, 6 and 12 months
frequency of alcohol consumption
at baseline, 3, 6 and 12 months
progression free survival
大体时间:at 12 months
median time between date of inclusion and date of first progression
at 12 months
overall survival
大体时间:at 12 months
median time between date of inclusion and date of death
at 12 months
sociodemographic, cancer-related, tobacco-related, alcohol-related, and psychiatric characteristics
大体时间:at baseline
at baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Corinne VANNIMENUS, MD、Centre Hospitalier Régional et Universitaire LILLE

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年4月1日

初级完成 (实际的)

2013年9月1日

研究完成 (实际的)

2014年9月1日

研究注册日期

首次提交

2012年7月19日

首先提交符合 QC 标准的

2012年7月19日

首次发布 (估计)

2012年7月23日

研究记录更新

最后更新发布 (实际的)

2018年1月24日

上次提交的符合 QC 标准的更新

2018年1月23日

最后验证

2014年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

physician assessment的临床试验

3
订阅